Impact of non-antibiotic drugs on the human intestinal microbiome

References

• Statistics (US) NC for H. Table 38, Prescription drug use in the past 30 days, by sex, race and Hispanic origin, and age: United States, selected years 1988–1994 through 2013–2016 [Internet]. National Center for Health Statistics (US); 2019 Available from: https://www.ncbi.nlm.nih.gov/books/NBK551099/table/ch3.tab38/ .
   Google Scholar
• Medicine Use and Spending in the U.S. [Internet]. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023#:~:text=The%20base%20case%20outlook%20in,over%20the%20past%20five%20years .
   Google Scholar
• European health interview survey - methodology - Statistics Explained [Internet]. Available from: https://ec.europa.eu/eurostat/statistics-explained/index.php/European_health_interview_survey_-_methodology.
   Google Scholar
• Barber N. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Qual Saf Health Care. 2005;14(3):227–228.
   PubMedGoogle Scholar
• Martin CB, Ogden CL. Prescription drug use in the United States, 2015–2016. Front Cell Infect Microbiol [Internet]. 2019:8.
   PubMed Web of Science ®Google Scholar
• Keeney KM, Yurist-Doutsch S, Arrieta M-C, et al. Effects of antibiotics on human microbiota and subsequent disease. Annu Rev Microbiol. 2014;68(1):217–235.
   PubMed Web of Science ®Google Scholar
• Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 2016;8:39.
   PubMed Web of Science ®Google Scholar
• Falony G, Joossens M, Vieira-Silva S, et al. Population-level analysis of gut microbiome variation. Science 2016;352(6285):560–564.
   PubMed Web of Science ®Google Scholar
• Zhernakova A, Kurilshikov A, Bonder MJ, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 2016;352(6285):565–569.
   PubMed Web of Science ®Google Scholar
• Vich Vila A, Collij V, Sanna S, et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun. 2020;11:362.
   PubMed Web of Science ®Google Scholar
• Maier L, Pruteanu M, Kuhn M, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555(7698):623–628.
   PubMed Web of Science ®Google Scholar
• Yeomans ND, Tulassay Z, Juhász L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998;338(11):719–726.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367(9528):2086–2100.
   PubMed Web of Science ®Google Scholar
• Kelly OB, Dillane C, Patchett SE, et al. The inappropriate prescription of oral proton pump inhibitors in the hospital setting: a prospective cross-sectional study. Dig Dis Sci. 2015;60:2280–2286.
   PubMed Web of Science ®Google Scholar
• Mat Saad AZ, Collins N, Lobo MM, et al. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59(1):31–34.
   PubMed Web of Science ®Google Scholar
• Bouwknegt M, Van Pelt W, Kubbinga ME. et al. Potential association between the recent increase in campylobacteriosis incidence in the Netherlands and proton-pump inhibitor use - an ecological study. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2014; 19.
   Google Scholar
• Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047–2056.
   PubMed Web of Science ®Google Scholar
• Janarthanan S, Ditah I, Adler DG, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Off J Am Coll Gastroenterol ACG. 2012;107:1001–1010.
   PubMed Web of Science ®Google Scholar
• Willems RPJ, van Dijk K, Ket JCF, et al. Evaluation of the association between gastric acid suppression and risk of intestinal colonization with multidrug-resistant microorganisms: a systematic review and meta-analysis. JAMA Intern Med. 2020;180:561–571.
   PubMed Web of Science ®Google Scholar
• Jackson MA, Goodrich JK, Maxan M-E, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 2016;65(5):749–756.
   PubMed Web of Science ®Google Scholar
• Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut 2016;65(5):740–748.
   PubMed Web of Science ®Google Scholar
• Clooney AG, Bernstein CN, Leslie WD, et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(9):974–984.
   PubMed Web of Science ®Google Scholar
• Seto CT, Jeraldo P, Orenstein R, et al. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome 2014;2(1):42.
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Toussaint NC, Chen SP, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883–885.
   PubMed Web of Science ®Google Scholar
• Koo SH, Deng J, Ang DSW, et al. Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore. Singapore Med J. 2019;60:512–521.
   PubMed Web of Science ®Google Scholar
• Shi Y-C, Cai S-T, Tian Y-P, et al. Effects of proton pump inhibitors on the gastrointestinal microbiota in gastroesophageal reflux disease. Genomics Proteomics Bioinf. 2019;17:52–63.
   PubMed Web of Science ®Google Scholar
• Castellani C, Singer G, Kashofer K, et al. The influence of proton pump inhibitors on the fecal microbiome of infants with gastroesophageal reflux—a prospective longitudinal interventional study. Front Cell Infect Microbiol [Internet]. 2017;7.
   PubMed Web of Science ®Google Scholar
• Horvath A, Rainer F, Bashir M, et al. Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis. Sci Rep. 2019;9:12000.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Cox IJ, Betrapally NS, et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol. 2014;307:G951–957.
   PubMed Web of Science ®Google Scholar
• Wellhöner F, Döscher N, Tergast TL, et al. The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. Scand J Gastroenterol. 2019;54(8):1033–1041.
   PubMed Web of Science ®Google Scholar
• Kim J-W, Jeong Y, Park S-J, et al. Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients. Rheumatol Oxf Engl. 2020.
   Google Scholar
• Jang S, Lebwohl B, Abrams JA, et al. Celiac disease serology and gut microbiome following proton pump inhibitor treatment. Medicine (Baltimore). 2020;99(35):e21488.
   PubMed Web of Science ®Google Scholar
• Hojo M, Asahara T, Nagahara A, et al. Gut microbiota composition before and after use of proton pump inhibitors. Dig Dis Sci. 2018;63:2940–2949.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Ishigami M, Honda T, et al. Influence of proton pump inhibitors on microbiota in chronic liver disease patients. Hepatol Int. 2019;13:234–244.
   PubMed Web of Science ®Google Scholar
• Vincent C, Stephens DA, Loo VG, et al. Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection. Microbiome 2013;1(1):18.
   PubMed Web of Science ®Google Scholar
• Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med. 2000;343(26):1925–1932.
   PubMed Web of Science ®Google Scholar
• Garcia-Mazcorro JF, Suchodolski JS, Jones KR, et al. Effect of the proton pump inhibitor omeprazole on the gastrointestinal bacterial microbiota of healthy dogs. FEMS Microbiol Ecol. 2012;80(3):624–636.
   PubMed Web of Science ®Google Scholar
• Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother. 1991;35:490–496.
   PubMed Web of Science ®Google Scholar
• Jonkers D, Stobberingh E, Stockbrügger R. Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. J Antimicrob Chemother. 1996;37:145–150.
   PubMed Web of Science ®Google Scholar
• Melchers K, Herrmann L, Mauch F, et al. Properties and function of the P type ion pumps cloned from Helicobacter pylori. Acta Physiol Scand Suppl. 1998;643:123–135.
   PubMedGoogle Scholar
• Vesper BJ, Jawdi A, Altman KW, et al. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab. 2009;10:84–89.
   PubMed Web of Science ®Google Scholar
• Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355:1834–1836.
   PubMed Web of Science ®Google Scholar
• Markovits N, Loebstein R, Halkin H, et al. The association of proton pump inhibitors and hypomagnesemia in the community setting. J Clin Pharmacol. 2014;54:889–895.
   PubMed Web of Science ®Google Scholar
• Yang Y-X, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology 2010;139:1115–1127.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Tanigawa T, Nadatani Y, et al. Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2013;45:390–395.
   Google Scholar
• Endo H, Sakai E, Taniguchi L, et al. Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry. Gastrointest Endosc. 2014;80(5):826–834.
   PubMed Web of Science ®Google Scholar
• Washio E, Esaki M, Maehata Y, et al. Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: a randomized, placebo-controlled trial. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2016;14:809–815.e1.
   PubMed Web of Science ®Google Scholar
• Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141:1314–1322, 1322.e1–5.
   Web of Science ®Google Scholar
• Tanigawa T, Watanabe T, Higashimori A, et al. Rebamipide ameliorates indomethacin-induced small intestinal damage and proton pump inhibitor-induced exacerbation of this damage by modulation of small intestinal microbiota. PLoS One. 2021;16. DOI: https://doi.org/10.1371/journal.pone.0245995.
   Google Scholar
• Poullis A, Foster R, Mendall MA. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol. 2003;15:573–574.
   PubMed Web of Science ®Google Scholar
• Yu YH, Han DS, Choi EY, et al. Is use of PPIs related to increased intraepithelial lymphocytes in the colon? Dig Dis Sci. 2012;57:2669–2674.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
   PubMed Web of Science ®Google Scholar
• Giugliano D, De Rosa N, Di Maro G, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care. 1993;16(10):1387–1390.
   PubMed Web of Science ®Google Scholar
• Shields WW, Thompson KE, Grice GA, et al. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a Pilot Trial. Ther Adv Gastroenterol. 2009;2(3):157–163.
   PubMedGoogle Scholar
• Bonora E, Cigolini M, Bosello O, et al. Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects. Curr Med Res Opin. 1984;9:47–51.
   PubMed Web of Science ®Google Scholar
• Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 2015;528(7581):262–266.
   PubMed Web of Science ®Google Scholar
• de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, et al. Metformin is associated with higher relative abundance of mucin-degrading akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care. 2017;40:54–62.
   PubMed Web of Science ®Google Scholar
• Nakajima H, Takewaki F, Hashimoto Y. et al. The effects of metformin on the gut microbiota of patients with type 2 diabetes: a two-center, quasi-experimental study. Life Basel Switz. 2020; 10.
   PubMed Web of Science ®Google Scholar
• Sun L, Xie C, Wang G, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018;24:1919–1929.
   PubMed Web of Science ®Google Scholar
• Zhang F, Wang M, Yang J, et al. Response of gut microbiota in type 2 diabetes to hypoglycemic agents. Endocrine 2019;66(3):485–493.
   PubMed Web of Science ®Google Scholar
• Elbere I, Kalnina I, Silamikelis I, et al. Association of metformin administration with gut microbiome dysbiosis in healthy volunteers. PLoS One. 2018;13:e0204317.
   PubMed Web of Science ®Google Scholar
• Elbere I, Silamikelis I, Dindune II, et al. Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients. PLoS One. 2020;15(10):e0241338.
   PubMed Web of Science ®Google Scholar
• Tong X, Xu J, Lian F, et al. Structural alteration of gut microbiota during the amelioration of human type 2 diabetes with hyperlipidemia by metformin and a traditional Chinese herbal formula: a multicenter, randomized, open label clinical trial. mBio [Internet]. 2018;9:e02392–17. Available from: https://mbio.asm.org/content/9/3/e02392–17.
   Google Scholar
• Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013;498(7452):99–103.
   PubMed Web of Science ®Google Scholar
• Pastor-Villaescusa B, Plaza-Díaz J, Egea-Zorrilla A, et al. Evaluation of the gut microbiota after metformin intervention in children with obesity: a metagenomic study of a randomized controlled trial. Biomed Pharmacother. 2021;134:111117.
   PubMed Web of Science ®Google Scholar
• Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23:850–858.
   PubMed Web of Science ®Google Scholar
• Bryrup T, Thomsen CW, Kern T, et al. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study. Diabetologia 2019;62(6):1024–1035.
   PubMed Web of Science ®Google Scholar
• Pryor R, Norvaisas P, Marinos G, et al. Host-microbe-drug-nutrient screen identifies bacterial effectors of metformin therapy. Cell. 2019;178:1299–1312.e29.
   PubMed Web of Science ®Google Scholar
• Napolitano A, Miller S, Nicholls AW, et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS ONE. 2014;9(7):9.
   Web of Science ®Google Scholar
• Shin N-R, Lee J-C, Lee H-Y, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut. 2014;63:727–735.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhao Y, Xu J, et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep. 2015;5:14405.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang R, Li X-F, et al. Bifidobacterium adolescentis supplementation ameliorates visceral fat accumulation and insulin sensitivity in an experimental model of the metabolic syndrome. Br J Nutr. 2012;107:1429–1434.
   PubMed Web of Science ®Google Scholar
• Gu Y, Wang X, Li J, et al. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nat Commun. 2017;8(1):1785. DOI: https://doi.org/10.1038/s41467-017-01682-2.
   Google Scholar
• Mastracci TL, Robertson MA, Mirmira RG, et al. Polyamine biosynthesis is critical for growth and differentiation of the pancreas. Sci Rep. 2015;5:13269.
   PubMed Web of Science ®Google Scholar
• Massey W, Brown JM. The gut microbial endocrine organ in type 2 diabetes. Endocrinology. 2020;162(2):bqaa235. DOI: https://doi.org/10.1210/endocr/bqaa235.
   Google Scholar
• Thompson PD, Panza G, Zaleski A, et al. Statin-associated side effects. J Am Coll Cardiol. 2016;67:2395–2410.
   PubMed Web of Science ®Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet Lond Engl. 2016;388:2532–2561.
   PubMed Web of Science ®Google Scholar
• Endo A. A gift from nature: the birth of the statins. Nat Med. 2008;14:1050–1052.
   PubMed Web of Science ®Google Scholar
• Kummen M, Solberg OG, Storm-Larsen C, et al. Rosuvastatin alters the genetic composition of the human gut microbiome. Sci Rep. 2020;10:5397.
   PubMed Web of Science ®Google Scholar
• Sun B, Li L, Zhou X. Comparative analysis of the gut microbiota in distinct statin response patients in East China. J Microbiol Seoul Korea. 2018;56:886–892.
   Google Scholar
• Khan TJ, Ahmed YM, Zamzami MA, et al. Atorvastatin treatment modulates the gut microbiota of the hypercholesterolemic patients. Omics J Integr Biol. 2018;22:154–163.
   PubMed Web of Science ®Google Scholar
• Bedarf JR, Hildebrand F, Coelho LP, et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients. Genome Med. 2017;9:39.
   PubMed Web of Science ®Google Scholar
• Vieira-Silva S, Falony G, Belda E, et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature 2020;581:310–315.
   PubMed Web of Science ®Google Scholar
• Liu Y, Song X, Zhou H, et al. Gut microbiome associates with lipid-lowering effect of rosuvastatin in vivo. Front Microbiol. 2018;9:530. DOI: https://doi.org/10.3389/fmicb.2018.00530.
   Google Scholar
• Karlson BW, Wiklund O, Palmer MK, et al. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother. 2016;2:212–217.
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk R, Baillie RA, Zhu H, et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS ONE. 2013;8(5). DOI:https://doi.org/10.1371/annotation/8e8e95ca-1ac3-4acf-abcb-223cd11ac1c1.
   Google Scholar
• Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev. 2010;62:1–96.
   PubMed Web of Science ®Google Scholar
• Tuteja S, Ferguson JF. The gut microbiome and response to cardiovascular drugs. 2019;12:421–429. Circ Genomic Precis Med.
   PubMed Web of Science ®Google Scholar
• Nolan JA, Skuse P, Govindarajan K, et al. The influence of rosuvastatin on the gastrointestinal microbiota and host gene expression profiles. Am J Physiol Gastrointest Liver Physiol. 2017;312:G488–G497.
   PubMed Web of Science ®Google Scholar
• Fu ZD, Cui JY, Klaassen CD. Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice. J Lipid Res. 2014;55:2576–2586.
   PubMed Web of Science ®Google Scholar
• Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem. 2007;42:3–27.
   PubMedGoogle Scholar
• Collet J-P, Thiele H, Barbato E, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289–1367.
   Web of Science ®Google Scholar
• Meyer-Kirchrath J, Schrör K. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract. Curr Med Chem. 2000;7:1121–1129.
   PubMed Web of Science ®Google Scholar
• Vincent C, Miller MA, Edens TJ, et al. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection. Microbiome 2016;4:12.
   PubMed Web of Science ®Google Scholar
• Bokulich NA, Battaglia T, Aleman JO, et al. Celecoxib does not alter intestinal microbiome in a longitudinal, diet-controlled study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2016;22:464–465.
   PubMed Web of Science ®Google Scholar
• Prizment AE, Staley C, Onyeaghala GC, et al. Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk. Aliment Pharmacol Ther. 2020;52:976–987.
   PubMed Web of Science ®Google Scholar
• Mäkivuokko H, Tiihonen K, Tynkkynen S, et al. The effect of age and non-steroidal anti-inflammatory drugs on human intestinal microbiota composition. Br J Nutr. 2010;103:227–234.
   PubMed Web of Science ®Google Scholar
• Rogers MM, Aronoff DM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2016;22:178.e1–178.e9.
   Google Scholar
• Robert A, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 1977;14:333–341.
   PubMed Web of Science ®Google Scholar
• Kinouchi T, Kataoka K, Bing SR, et al. Culture supernatants of Lactobacillus acidophilus and Bifidobacterium adolescentis repress ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug by suppressing unbalanced growth of aerobic bacteria and lipid peroxidation. Microbiol Immunol. 1998;42:347–355.
   PubMed Web of Science ®Google Scholar
• Zhang J, Sun Y, Wang R, et al. Gut microbiota-mediated drug-drug interaction between amoxicillin and aspirin. Sci Rep. 2019;9:16194.
   PubMed Web of Science ®Google Scholar
• Liang X, Bittinger K, Li X, et al. Bidirectional interactions between indomethacin and the murine intestinal microbiota. eLife 2015;4:e08973.
   PubMed Web of Science ®Google Scholar
• Clemente JC, Ursell LK, Parfrey LW, et al. The impact of the gut microbiota on human health: an integrative view. Cell 2012;148:1258–1270.
   PubMed Web of Science ®Google Scholar